Almac’s
Diagnostics business unit today announced the launch of its Bioinformatics Consultancy service.
Almac’s Bioinformatics consultancy supports discovery and development of biomarkers as well as enabling an in-depth understanding of biology by partnering with customers in the pharmaceutical, biotech, and diagnostics setting from the initial study design through to the interpretation of data results.
The consultancy service offers a range of customizable bioinformatics and biostatistics solutions which include; Biomarker Discovery and Development, Exploratory Analysis, Mechanistic, and Functional Analysis, Traditional and Next Generation Sequencing Data Analysis, Biostatistics, and Data Integration.
The solutions are delivered through a large bioinformatics team from a wide range of disciplines including biology, medicine, mathematics, and biostatistics. In addition the team also has experience in molecular and cell biology, drug discovery and development, and diagnostic product development.
Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic business unit said:
Bioinformatics has always been a key strength for us in Almac. Over the years we have built up a world class team of bioinformaticians and biostatisticians. This team has provided invaluable support for both our internal research and our external work. The launch of the full bioinformatics consultancy business is the next logical step in enabling our customer’s to access this important resource”.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.